Weight & body composition
Semaglutide (injectable) vs Tirzepatide
Both are authorised incretin-based medicines with large human datasets; compare mechanism, indication, trial populations, outcomes, tolerability and current.
At a glance
Semaglutide (injectable)
Tirzepatide
Human evidence
Extensive Phase III evidence supports weight loss with regulated semaglutide. SELECT demonstrated cardiovascular benefit in a defined population, and STEP 9 showed improved knee-OA pain/function in adults with obesity.
Large Phase III obesity evidence shows substantial weight loss. SURMOUNT-OSA additionally demonstrated large reductions in sleep-apnea severity in adults with obesity and moderate-to-severe OSA.
Research focus
Obesity, weight management, cardiovascular outcomes, heart failure, osteoarthritis, type 2 diabetes
Type 2 diabetes, obesity, weight management
Regulatory status
Wegovy (semaglutide) is authorised in the EU for weight management in defined adults and adolescents; authorisation and dosing are product-, route-, indication- and jurisdiction-specific.
Tirzepatide is authorised in licensed products such as Mounjaro for type 2 diabetes and adult weight management in the EU; authorization is product- and jurisdiction-specific.
Route / formulation
Evidence for licensed pre-filled injection pens cannot establish identity, concentration, sterility or equivalence of unverified semaglutide vials or non-authorised products.
Unverified research-market material or non-authorised pens are not equivalent to licensed tirzepatide medicines merely because the active-ingredient name matches.
Direct head-to-head obesity trial evidence exists in development literature; page must use matched doses/populations and current authorised labels Both are authorised incretin-based medicines with large human datasets; compare mechanism, indication, trial populations, outcomes, tolerability and current product status rather than declaring a universal winner.